DOCSLIB.ORG

Disruption of the Alox5ap Gene Ameliorates Focal Ischemic Stroke: Possible Consequence of Impaired Leukotriene Biosynthesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Disruption of the Alox5ap Gene Ameliorates Focal Ischemic Stroke: Possible Consequence of Impaired Leukotriene Biosynthesis Ström et al. BMC Neuroscience 2012, 13:146 http://www.biomedcentral.com/1471-2202/13/146 RESEARCH ARTICLE Open Access Disruption of the alox5ap gene ameliorates focal ischemic stroke: possible consequence of impaired leukotriene biosynthesis Jakob O Ström1, Tobias Strid2 and Sven Hammarström2* Abstract Background: Leukotrienes are potent inflammatory mediators, which in a number of studies have been found to be associated with ischemic stroke pathology: gene variants affecting leukotriene synthesis, including the FLAP (ALOX5AP) gene, have in human studies shown correlation to stroke incidence, and animal studies have demonstrated protective properties of various leukotriene-disrupting drugs. However, no study has hitherto described a significant effect of a genetic manipulation of the leukotriene system on ischemic stroke. Therefore, we decided to compare the damage from focal cerebral ischemia between wild type and FLAP knockout mice. Damage was evaluated by infarct staining and a functional test after middle cerebral artery occlusion in 20 wild type and 20 knockout male mice. Results: Mortality-adjusted median infarct size was 18.4 (3.2-76.7) mm3 in the knockout group, compared to 72.0 (16.7-174.0) mm3 in the wild type group (p < 0.0005). There was also a tendency of improved functional score in the knockout group (p = 0.068). Analysis of bone marrow cells confirmed that knockout animals had lost their ability to form leukotrienes. Conclusions: Since the local inflammatory reaction after ischemic stroke is known to contribute to the brain tissue damage, the group difference seen in the current study could be a consequence of a milder inflammatory reaction in the knockout group. Our results add evidence to the notion that leukotrienes are important in ischemic stroke, and that blocked leukotriene production ameliorates cerebral damage. Keywords: Brain infarction, Leukotrienes, Alox5ap protein, FLAP, Mice, Middle cerebral artery occlusion Background inflammatory cytokines and infiltration of various in- Ischemic stroke is one of the leading causes of death and flammatory cells, including neutrophils, T-cells and long-term disability in the world. Despite the allocation monocytes/macrophages, into the damaged tissue. In- of huge research efforts in recent years, treatment flammation contributes to tissue damage, and especially options for ischemic stroke remain few. Therefore, the early inflammatory cell infiltration and cytokine pro- investigations into the pathophysiological intricacies of duction seem to be predominantly deleterious [1]. the disease are crucial to provide new drug targets. Mounting evidence indicates that leukotrienes (LTs), a Inflammation is a prominent feature of stroke patho- group of potent inflammatory mediators [2], have an im- physiology, and has attracted substantial research inter- portant role in cerebral ischemia, and that components est. The massive cell death in the infarct area triggers an involved in the LT cascade may be attractive drug acute and prolonged inflammatory process in the brain, targets. LTs are formed from arachidonic acid (AA) by characterized by activation of microglia, production of 5-lipoxygenase (5-LO) upon immunological or inflam- matory challenge. 5-LO activating protein (FLAP) is an integral membrane protein localized to the nuclear enve- * Correspondence: [email protected] lope and endoplasmic reticulum. Both 5-LO and FLAP 2Division of Cell Biology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden are required for formation of LTA4 from endogenous Full list of author information is available at the end of the article AA [3-8], and LTA4, is the precursor of all AA-derived © 2012 Ström et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Ström et al. BMC Neuroscience 2012, 13:146 Page 2 of 9 http://www.biomedcentral.com/1471-2202/13/146 effector LTs. The expression of 5-LO [9] and LT recep- The use of genetically modified animals is an import- tors [10-13] is affected by cerebral ischemia, and the ant tool in the elucidation of biological mechanisms. importance of eicosanoids has been proposed from the However, in the case of LT effects on stroke, such stud- observation that AA concentrations are highest in ische- ies remain scarce. The only one we are aware of investi- mic brain regions most sensitive to stroke [14]. Human gated the effect of disrupting the 5-LO gene in mice, but genetic studies have demonstrated a significant correl- no significant effects on focal cerebral ischemia were ation between stroke risk and polymorphisms in several seen [31]. Because of the suggested importance of FLAP of the LT-associated genes, e.g. ALOX5AP encoding in human stroke studies, we decided to investigate the FLAP [15-17], as well as genes encoding LTC4 synthase effect of FLAP gene knockout in a rodent middle cere- [16,18] and cysteinyl (Cys) LT receptors [16]. Also, a bral artery occlusion (MCAo) model. The hypothesis large Swedish epidemiologic study recently showed that was that the decreased LT production in the genetically intake of montelukast, a CysLT1R antagonist, was asso- modified mice would ameliorate the damage from ische- ciated with a decreased risk of recurrent stroke [19]. mic stroke. Furthermore, animal studies have demonstrated that drugs interfering with components of the LT pathway, Results such as 5-LO [20-22] and LT receptors [23-28], amelior- FLAP knockout mice do not produce leukotrienes ate cerebral ischemic damage. Effects mediated by both LTA4 is an obligatory intermediate in the biosynthesis of of the established CysLT receptors, CysLT1R [13,24,26- LTB4 and LTC4 [32]. It is unstable and thus difficult to 28] and CysLT2R [10], appear to be involved in ischemic measure by direct methods. Therefore, we measured its brain injury. Furthermore, the proposed CysLT receptor downstream product LTB4 which is efficiently formed GPR17 was found to be up-regulated in damaged tissues, from LTA4 by the widely expressed enzyme LTA4 hydro- and knockout of the GPR17 gene reduced neuronal in- lase. Bone marrow cells from wild type and knockout jury after ischemia [29,30]. mice were incubated without cysteine with AA and LTC LTB 80 Reference 3.244 2.275 compounds 60 40 nm [mAU] 0.443 20 0.961 3.874 1.596 0 Absorbance at 270 0 1234 5 Time [min] 0.457 0.982 80 FLAP +/+ 3.174 60 40 nm [mAU] 20 2.419 2.715 1.575 0 1.871 Absorbance at 270 0 1234 5 Time [min] 0.976 0.455 80 FLAP -/- 60 40 nm [mAU] 20 1.875 2.387 2.580 2.737 3.244 0 Absorbance at 270 0 1234 5 Time [min] Figure 1 Leukotriene formation was blocked in FLAP knockout mice. Bone marrow cells obtained from wild type and FLAP knockout animals were incubated with 50 μM AA and 20 μM calcium ionophore A23187 for 20 min at 37°C. Reactions were stopped with ice cold methanol and supernatants were analyzed by RP-HPLC as described in Materials and Methods. The absorbance at 270 nm, corrected for stray absorbance at 360 nm, was recorded versus time. Retention times in minutes are indicated for each component in the chromatograms. Upper panel: analysis of synthetic LTB4 and LTC4. Middle panel: LTB4 was formed by bone marrow cells from wild type mice, but not from knockout mice (lower panel). Ström et al. BMC Neuroscience 2012, 13:146 Page 3 of 9 http://www.biomedcentral.com/1471-2202/13/146 calcium ionophore A23187. The lack of cysteine pre- (0.40-0.60) and 0.65 (0.53-0.70), respectively. The mice vents formation of LTC4 [33,34] whereas formation of in both groups were severely affected by the ischemic LTB4 proceeds normally. RP-HPLC analyses showed that stroke, and as much as 91% of the wild type and 60% of LTB4 was formed by wild type, but not by FLAP knock- the knockout animals scored maximally (1.00 = 100% of out, bone marrow cells (Figure 1). swings to the right) in the tail swing test, thus decreasing the test sensitivity. Despite this, a trend of better out- FLAP knockout decreased mortality-adjusted infarct size come, which however did not reach statistical signifi- In the wild type group, two of the included animals died cance (p = 0.068), was seen in the knockout group. within 24 h after MCAo, while no included animals died Mortality-adjusted median tail swing index (proportion in the FLAP knockout group. Mortality-adjusted median of right side swings) was 1.00 (1.00-1.00) in the wild type infarct size was 18.4 (3.2-76.7) mm3 in the knockout group, compared to 1.00 (0.90-1.00) in the knockout group, compared to 72.0 (16.7-174.0) mm3 in the wild group (Figure 3). type group (p < 0.0005; Figure 2). Perioperative physiological monitoring FLAP knockout had no significant effect on mortality- The physiological variables monitored during MCAo adjusted tail swing test performance were similar between the two groups, as presented in Before MCAo, the wild type and knockout groups Table 1, indicating that they responded similarly to the scored close to the theoretical baseline index of 0.50 anesthesia. (equal number of swings to the left and right), with tail swing indices (proportion of right-sided swings) of 0.50 p=0.068 p<0.0005 : 2 : 0 : 2 : 0 1.0 200 180 0.8 160 ] 3 140 0.6 120 100 0.4 80 60 Infarct size [mm 40 0.2 20 Proportion of right side swings 0 0 WT KO WT KO Figure 2 Infarct sizes were decreased in FLAP knockout mice.In Figure 3 Tendency of improved functional outcome in FLAP terms of mortality-adjusted median infarct size, the knockout knockout mice.
Load more

Recommended publications
  • Eicosanoids in Carcinogenesis
    4open 2019, 2,9 © B.L.D.M. Brücher and I.S. Jamall, Published by EDP Sciences 2019 https://doi.org/10.1051/fopen/2018008 Special issue: Disruption of homeostasis-induced signaling and crosstalk in the carcinogenesis paradigm “Epistemology of the origin of cancer” Available online at: Guest Editor: Obul R. Bandapalli www.4open-sciences.org REVIEW ARTICLE Eicosanoids in carcinogenesis Björn L.D.M. Brücher1,2,3,*, Ijaz S. Jamall1,2,4 1 Theodor-Billroth-Academy®, Germany, USA 2 INCORE, International Consortium of Research Excellence of the Theodor-Billroth-Academy®, Germany, USA 3 Department of Surgery, Carl-Thiem-Klinikum, Cottbus, Germany 4 Risk-Based Decisions Inc., Sacramento, CA, USA Received 21 March 2018, Accepted 16 December 2018 Abstract- - Inflammation is the body’s reaction to pathogenic (biological or chemical) stimuli and covers a burgeoning list of compounds and pathways that act in concert to maintain the health of the organism. Eicosanoids and related fatty acid derivatives can be formed from arachidonic acid and other polyenoic fatty acids via the cyclooxygenase and lipoxygenase pathways generating a variety of pro- and anti-inflammatory mediators, such as prostaglandins, leukotrienes, lipoxins, resolvins and others. The cytochrome P450 pathway leads to the formation of hydroxy fatty acids, such as 20-hydroxyeicosatetraenoic acid, and epoxy eicosanoids. Free radical reactions induced by reactive oxygen and/or nitrogen free radical species lead to oxygenated lipids such as isoprostanes or isolevuglandins which also exhibit pro-inflammatory activities. Eicosanoids and their metabolites play fundamental endocrine, autocrine and paracrine roles in both physiological and pathological signaling in various diseases. These molecules induce various unsaturated fatty acid dependent signaling pathways that influence crosstalk, alter cell–cell interactions, and result in a wide spectrum of cellular dysfunctions including those of the tissue microenvironment.
    [Show full text]
  • Characterization of Human Glutathione-Dependent Microsomal Prostaglandin E Synthase-1
    Department of Medical Biochemistry and Biophysics, Division of Chemistry II, Karolinska Institutet, 171 77 Stockholm, Sweden Characterization of human glutathione-dependent microsomal prostaglandin E synthase-1 Staffan Thorén Stockholm 2003 ABSTRACT Prostaglandins (PGs) are lipid mediators, which act as local hormones. PGs are formed in most cells and are synthesized de novo from membrane-released arachidonic acid (AA) upon cell activation. Prostaglandin H synthase (PGHS) –1 or 2, also referred to as COX-1 and COX-2, metabolize AA to PGH2, which is subsequently converted in a cell-specific manner by downstream enzymes to biologically active prostanoids, i.e. PGE2, PGD2, PGF2α, PGI2 or TXA2. PGHS-1 is constitutively expressed in many cells and is mainly involved in housekeeping functions, such as vascular homeostasis, whereas PGHS-2 can be induced by proinflammatory cytokines at sites of inflammation. Prostaglandin E synthase (PGES) specifically catalyzes the conversion of PGH2 to PGE2, which is a biologically potent prostaglandin involved in several pathological conditions; including pain, fever, inflammation and possibly some forms of cancers and neurodegenerative diseases. mPGES-1 was initially identified as a homologue to microsomal glutathione transferase-1 (MGST1) with 37% identity on the amino acid sequence level and referred to as MGST1-like 1 (MGST1- L1). Based on the properties of MGST1-L1, regarding size, amino acid sequence, hydropathy and membrane localization, the protein was identified as a member of the MAPEG-superfamily (membrane- associated proteins in eicosanoid and glutathione metabolism). The superfamily consists of 16-18 kDa, integral membrane proteins with typical hydropathy profiles and diverse functions. The MAPEG family comprises six human members, which in addition to mPGES-1 are; 5-lipoxygenase activating protein (FLAP), leukotriene C4 synthase (LTC4S), MGST1, MGST2 and MGST3.
    [Show full text]
  • Original Articles Enhancement of Leukotriene B4 Release in Stimulated Asthmatic Neutrophils by Platelet Activating Factor
    1024 Thorax 1997;52:1024±1029 Thorax: first published as 10.1136/thx.52.12.1024 on 1 December 1997. Downloaded from Original articles Enhancement of leukotriene B4 release in stimulated asthmatic neutrophils by platelet activating factor Kunihiko Shindo, Kohei Koide, Motonori Fukumura Abstract of phospholipase A2 and acetyltransferase on Background ± The role of platelet ac- membrane alkylacyl phospholipids. PAF was tivating factor (PAF) in asthma remains originally described as a substance released controversial. The priming eVect of PAF from basophils sensitised with IgE.1 on leukotriene B4 (LTB4) release, 5-lip- The stimulation of neutrophils by PAF res- oxygenase activity, and intracellular cal- ults in the release of lysosomal enzymes and cium levels in asthmatic neutrophils was superoxide anions and the generation of leuko- 23 examined. triene (LT) B4. The biological eVects of Methods ±LTB4 and other lipoxygenase PAF, including airway microvascular leakage, metabolites in neutrophils obtained from bronchoconstriction, sustained increase in 17 asthmatic patients and 15 control sub- bronchial smooth muscle responsiveness, and jects were measured by reverse phase-high pulmonary vasoconstriction, mimic many clin- performance liquid chromatography (RP- ical features of asthma. Thus, PAF has been HPLC). Intracellular calcium levels were considered an important mediator in asthma monitored using the ¯uorescent probe as well as in other lung disorders.4 However, fura-2. clinical studies56 with PAF receptor antagonist Results ± The mean (SD)
    [Show full text]
  • Montelukast, a Leukotriene Receptor Antagonist, Reduces the Concentration of Leukotrienes in the Respiratory Tract of Children with Persistent Asthma
    Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma Benjamin Volovitz, MD,a,b Elvan Tabachnik, MD,c Moshe Nussinovitch, MD,b Biana Shtaif, MSc,b Hanna Blau, MD,a Irit Gil-Ad, PhD,b Abraham Weizman, MD,b and Itzhak Varsano, MDa,b Petah Tikva, Tel Aviv, and Rehovot, Israel Background: Leukotrienes are bronchoactive mediators secreted by inflammatory cells in the respiratory mucosa on Abbreviations used exposure to asthma triggers. BAL: Bronchoalveolar lavage Objective: We investigated the effect of montelukast, a CysLT1: Cysteinyl leukotriene 1 (receptor) leukotriene receptor antagonist, on the release of leukotrienes ECP: Eosinophilic cationic protein in the respiratory mucosa of children with persistent asthma. LTC4: Leukotriene C4 Method: Twenty-three children aged 6 to 11 years with moder- LTD4: Leukotriene D4 ately severe asthma were treated in a cross-over design start- LTE4: Leukotriene E4 ing, after a 2-week run in period, with either montelukast (n = 12) or cromolyn (n = 11) for 4 weeks with a 2-week washout period between treatments. Twelve of them were then treated Cysteinyl leukotrienes are potent proinflammatory with either montelukast or beclomethasone for 6 months. The mediators produced from a variety of inflammatory use of β -agonists was recorded on a diary card. The concen- 2 cells, including mast cells, eosinophils, basophils and tration of leukotriene C4 (LTC4) was measured by HPLC in nasal washes obtained before and at the end of each treatment macrophages. Leukotriene C4 (LTC4) is metabolized period. Eosinophilic cationic protein (ECP) was measured in enzymatically to leukotriene D4 (LTD4) and subsequent- the nasal washes by RIA.
    [Show full text]
  • Boswellic Acids in Chronic Inflammatory Diseases Review
    H. P. T. Ammon Boswellic Acids in Chronic Inflammatory Diseases Review Abstract CHE: Cholinesterase Con A: Concanavalin A Oleogum resins from Boswellia species are usedin traditional COX1: Cyclooxygenase 1 medicine in India and African countries for the treatment of a COX2: Cyclooxygenase 2 variety of diseases. Animal experiments showed anti-inflamma- cPLA: Phospholipase A tory activity of the extract. The mechanism of this action is due to CRP: C-reactive protein some boswellic acids. It is different from that of NSAID and is EC50: Effective concentration 50 relatedto components of the immune system. The most evident ESR: Erythrocyte sedimentation rate action is the inhibition of 5-lipoxygenase. However, other factors FEV1: Forcedexpiratory volume in 1 sec (liters) such as cytokines (interleukins andTNF- a) andthe complement FLAP: 5-Lipoxygenase activating protein system are also candidates. Moreover, leukocyte elastase and fMLP: n-Formyl-methionyl-leucyl-phenylalanin oxygen radicals are targets. Clinical studies, so far with pilot FVC: Forcedvital capacity (liters) character, suggest efficacy in some autoimmune diseases includ- HAB: Homöopathisches Arzneibuch ing rheumatoidarthritis, Crohn's disease,ulcerative colitis and (German homeopathic pharmacopoeia) bronchial asthma. Side effects are not severe when compared to 5-HETE: 5-Hydroxyeicosatetraenoic acid modern drugs used for the treatment of these diseases. 12-HETE: 12-Hydroxyeicosatetraenoic acid 12-HHT: 12-Hydroxyheptadecatrienoic acid Key words HLE: Human leucocyte elastase Boswellic
    [Show full text]
  • LEUKOTRIENE A4 HYDROLASE Martin J. Mueller
    Department of Medical Biochemistry and Biophysics, Division of Chemistry II, Karolinska Institutet, 171 77 Stockholm, SWEDEN LEUKOTRIENE A4 HYDROLASE Identification of amino acid residues involved in catalyses and substrate-mediated inactivation Martin J. Mueller Stockholm 2001 Published and printed by Karolinska University Press Box 200, SE-171 77 Stockholm, Sweden © Martin J. Mueller, 2001 ISBN 91-628-4934-4 Abstract Leukotriene (LT) A4 hydrolase catalyzes the committed step in the biosynthesis of LTB4, a classical chemoattractant and immune-modulating lipid mediator involved in inflammation, host-defense against infections, and systemic, PAF-mediated, lethal shock. LTA4 hydrolase is a bifunctional zinc metalloenzyme with a chloride-stimulated arginyl aminopeptidase activity. When exposed to its lipid substrate LTA4, the enzyme is inactivated and covalently modified in a process termed suicide inactivation, which puts a restrain on the enzyme's ability to form the biologically active LTB4. In the present thesis, chemical modification with a series of amino acid-specific reagents, in the presence and absence of competitive inhibitors, was used to identify catalytically important residues at the active site. Thus, using differential labeling techniques, modification with the tyrosyl reagents N-acetylimidazole and tetranitromethane revealed the presence of two catalytically important Tyr residues. Likewise, modification with 2,3-butanedione and phenylglyoxal indicated that three Arg residues were located at, or near, the active center of the enzyme. Using differential Lys-specific peptide mapping of untreated and suicide inactivated LTA4 hy- drolase, a 21 residue peptide termed K21, was identified that is involved in binding of LTA4 to the native protein. Isolation and amino acid sequencing of a modified form of K21, revealed that Tyr- 378 is the site of attachment between LTA4 and the protein.
    [Show full text]
  • Biological Effects of Inhaled Hydraulic Fracturing Sand Dust VII. Neuroinflammation and Altered Synaptic Protein Expression
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Toxicol Manuscript Author Appl Pharmacol Manuscript Author . Author manuscript; available in PMC 2020 December 24. Published in final edited form as: Toxicol Appl Pharmacol. 2020 December 15; 409: 115300. doi:10.1016/j.taap.2020.115300. Biological effects of inhaled hydraulic fracturing sand dust VII. Neuroinflammation and altered synaptic protein expression Krishnan Sriram*, Gary X. Lin, Amy M. Jefferson, Walter McKinney, Mark C. Jackson, Amy Cumpston, Jared L. Cumpston, James B. Cumpston, Howard D. Leonard, Michael Kashon, Jeffrey S. Fedan Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV 26505, United States of America Abstract Hydraulic fracturing (fracking) is a process used to recover oil and gas from shale rock formation during unconventional drilling. Pressurized liquids containing water and sand (proppant) are used to fracture the oil- and natural gas-laden rock. The transportation and handling of proppant at well sites generate dust aerosols; thus, there is concern of worker exposure to such fracking sand dusts (FSD) by inhalation. FSD are generally composed of respirable crystalline silica and other minerals native to the geological source of the proppant material. Field investigations by NIOSH suggest that the levels of respirable crystalline silica at well sites can exceed the permissible exposure limits. Thus, from an occupational safety perspective, it is important to evaluate the potential toxicological effects of FSD, including any neurological risks. Here, we report that acute inhalation exposure of rats to one FSD, i.e., FSD 8, elicited neuroinflammation, altered the expression of blood brain barrier-related markers, and caused glial changes in the olfactory bulb, hippocampus and cerebellum.
    [Show full text]
  • Disruption of the Alox5ap Gene Ameliorates Focal Ischemic Stroke: Possible Consequence of Impaired Leukotriene Biosynthesis
    Disruption of the alox5ap gene ameliorates focal ischemic stroke: possible consequence of impaired leukotriene biosynthesis Jakob Ström, Tobias Strid and Sven Hammarström Linköping University Post Print N.B.: When citing this work, cite the original article. Original Publication: Jakob Ström, Tobias Strid and Sven Hammarström, Disruption of the alox5ap gene ameliorates focal ischemic stroke: possible consequence of impaired leukotriene biosynthesis, 2012, BMC neuroscience (Online), (13). http://dx.doi.org/10.1186/1471-2202-13-146 Licencee: BioMed Central http://www.biomedcentral.com/ Postprint available at: Linköping University Electronic Press http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-89759 Ström et al. BMC Neuroscience 2012, 13:146 http://www.biomedcentral.com/1471-2202/13/146 RESEARCH ARTICLE Open Access Disruption of the alox5ap gene ameliorates focal ischemic stroke: possible consequence of impaired leukotriene biosynthesis Jakob O Ström1, Tobias Strid2 and Sven Hammarström2* Abstract Background: Leukotrienes are potent inflammatory mediators, which in a number of studies have been found to be associated with ischemic stroke pathology: gene variants affecting leukotriene synthesis, including the FLAP (ALOX5AP) gene, have in human studies shown correlation to stroke incidence, and animal studies have demonstrated protective properties of various leukotriene-disrupting drugs. However, no study has hitherto described a significant effect of a genetic manipulation of the leukotriene system on ischemic stroke. Therefore, we decided to compare the damage from focal cerebral ischemia between wild type and FLAP knockout mice. Damage was evaluated by infarct staining and a functional test after middle cerebral artery occlusion in 20 wild type and 20 knockout male mice.
    [Show full text]
  • Human Leukotriene C4 Synthase at 4.5 A˚Resolution in Projection
    Structure, Vol. 12, 2009–2014, November, 2004, 2004 Elsevier Ltd. All rights reserved. DOI 10.1016/j.str.2004.08.008 Human Leukotriene C4 Synthase at 4.5 A˚ Resolution in Projection Ingeborg Schmidt-Krey,1,* Yoshihide Kanaoka,2 MGST3, FLAP, and microsomal prostaglandin E syn- Deryck J. Mills,1 Daisuke Irikura,2 thase-1 (Jakobsson et al., 1999). The amino acid se- 1 2 2 Winfried Haase, Bing K. Lam, K. Frank Austen, quence of the human LTC4S is 44%, 31%, and 27% and Werner Ku¨ hlbrandt1 identical to that of human MGST2, FLAP, and MGST3, 1Department of Structural Biology respectively, and has less similarity to that of MGST1 Max-Planck-Institute of Biophysics (18% identity) and microsomal prostaglandin E syn- Marie-Curie-Strasse 15 thase-1 (14% identity). 60439 Frankfurt am Main LTC4S shows overlapping and distinct enzymatic Germany properties as compared to other members of the MAPEG 2 Department of Medicine family. MGST2 (Jakobsson et al., 1996) and MGST3 (Ja- Harvard Medical School and kobsson et al., 1997) can also conjugate LTA4 as well Division of Rheumatology, Immunology, and Allergy as xenobiotics with reduced glutathione in vitro, while Brigham and Women’s Hospital LTC4S has strict substrate specificity for LTA4 (Nicholson 2ϩ One Jimmy Fund Way et al., 1993). LTC4S activity is augmented by Mg ions Boston, Massachusetts 02115 and phosphatidylcholine and is inhibited by Co2ϩ ions (Nicholson et al., 1992a). N-ethylmaleimide, a sulfhydryl group reactive agent, activates MGST1 (Morgenstern et Summary al., 1980) but inhibits LTC4S activity in the human leuke- mic monoblast cell line, U937 (Nicholson et al., 1992b) and the recombinant human LTC4S (B.K.L., unpublished Leukotriene (LT) C4 synthase, an 18 kDa integral mem- results).
    [Show full text]
  • Cysteinyl Leukotrienes As Potential Pharmacological Targets for Cerebral Diseases
    Hindawi Mediators of Inflammation Volume 2017, Article ID 3454212, 15 pages https://doi.org/10.1155/2017/3454212 Review Article Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases 1 1 1 1,2 2 Paolo Gelosa, Francesca Colazzo, Elena Tremoli, Luigi Sironi, and Laura Castiglioni 1Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, 20138 Milan, Italy 2Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Giuseppe Balzaretti 9, 20133 Milan, Italy Correspondence should be addressed to Luigi Sironi; [email protected] Received 26 January 2017; Revised 10 April 2017; Accepted 19 April 2017; Published 18 May 2017 Academic Editor: Elzbieta Kolaczkowska Copyright © 2017 Paolo Gelosa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cysteinyl leukotrienes (CysLTs) are potent lipid mediators widely known for their actions in asthma and in allergic rhinitis. Accumulating data highlights their involvement in a broader range of inflammation-associated diseases such as cancer, atopic dermatitis, rheumatoid arthritis, and cardiovascular diseases. The reported elevated levels of CysLTs in acute and chronic brain lesions, the association between the genetic polymorphisms in the LTs biosynthesis pathways and the risk of cerebral pathological events, and the evidence from animal models link also CysLTs and brain diseases. This review will give an overview of how far research has gone into the evaluation of the role of CysLTs in the most prevalent neurodegenerative disorders (ischemia, Alzheimer’s and Parkinson’s diseases, multiple sclerosis/experimental autoimmune encephalomyelitis, and epilepsy) in order to understand the underlying mechanism by which they might be central in the disease progression.
    [Show full text]
  • Concentration-Dependent Noncysteinyl Leukotriene Type 1 Receptor-Mediated Inhibitory Activity of Leukotriene Receptor Antagonist
    Concentration-Dependent Noncysteinyl Leukotriene Type 1 Receptor-Mediated Inhibitory Activity of Leukotriene Receptor Antagonists This information is current as of September 27, 2021. Grzegorz Woszczek, Li-Yuan Chen, Sara Alsaaty, Sahrudaya Nagineni and James H. Shelhamer J Immunol 2010; 184:2219-2225; Prepublished online 18 January 2010; doi: 10.4049/jimmunol.0900071 Downloaded from http://www.jimmunol.org/content/184/4/2219 References This article cites 38 articles, 10 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/184/4/2219.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Concentration-Dependent Noncysteinyl Leukotriene Type 1 Receptor-Mediated Inhibitory Activity of Leukotriene Receptor Antagonists Grzegorz Woszczek,*,†,1 Li-Yuan Chen,*,1 Sara Alsaaty,* Sahrudaya Nagineni,* and James H. Shelhamer* The use of cysteinyl leukotriene receptor antagonists (LTRAs) for asthma therapy has been associated with a significant degree of interpatient variability in response to treatment.
    [Show full text]
  • Emerging Role of Cysteinyl Leukotrienes in Cancer
    Emerging role of cysteinyl leukotrienes in cancer Lou Saier1 and Olivier Peyruchaud2 1INSERM U1033 2INSERM September 11, 2020 Abstract Cysteinyl leukotrienes (CysLTs) are inflammatory lipid mediators that play a central role in the pathophysiology of several inflammatory diseases. Recently, there has been an increased interest in determining how these lipid mediators orchestrate tumor development and metastasis through promoting a pro-tumoral microenvironment. Upregulation of CysLTs receptors and CysLTs production is found in a number of cancers and has been associated with increased tumorigenesis. Understanding the molecular mechanisms underlying the role of CysLTs and their receptors in cancer progression will help investigate the potential of targeting CysLTs signaling for anti-cancer therapy. This review gives an overview of the biological effects of CysLTs and their receptors, along with current knowledge of their regulation and expression. It also provides a recent update on the molecular mechanisms that have been postulated to explain their role in tumorigenesis and on the potential of anti-CysLTs in the treatment of cancer. KEYWORDS Cysteinyl leukotrienes, inflammation, cancer, metastasis INTRODUCTION Cysteinyl leukotrienes (CysLTs) are one of the major constituents of the eicosanoid family of bioactive in- flammatory lipid-mediators. They are rapidly generated at the site of inflammation in response to immuno- logical and nonimmunological stimuli following the release of arachidonic acid through the 5-lipoxygenase (5-LOX) pathway (Figure 1A). The term CysLTs includes leukotriene C4(LTC4), leukotriene D4(LTD4), and leukotriene E4(LTE4); they are structurally different from leukotriene A4 (LTA4) and leukotriene B4 (LTB4), which are commonly known as leukotrienes (LTs). Leukotrienes exhibit diverse biological effects such as contraction of bronchial smooth muscle, stimulation of vascular permeability, and attraction and activation of leukocytes (Hammarstr¨om,1983).
    [Show full text]